These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20331626)

  • 41. Loss of p53, rather than beta-catenin overexpression, induces survivin-mediated resistance to apoptosis in an esophageal cancer cell line.
    Chang E; Donahue J; Smith A; Hornick J; Rao JN; Wang JY; Battafarano RJ
    J Thorac Cardiovasc Surg; 2010 Jul; 140(1):225-32. PubMed ID: 20236666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of ErbB2 enhances radiation-induced NF-kappaB activation.
    Guo G; Wang T; Gao Q; Tamae D; Wong P; Chen T; Chen WC; Shively JE; Wong JY; Li JJ
    Oncogene; 2004 Jan; 23(2):535-45. PubMed ID: 14724581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting beta-catenin signaling to induce apoptosis in human breast cancer cells by z-guggulsterone and Gugulipid extract of Ayurvedic medicine plant Commiphora mukul.
    Jiang G; Xiao X; Zeng Y; Nagabhushanam K; Majeed M; Xiao D
    BMC Complement Altern Med; 2013 Aug; 13():203. PubMed ID: 23914993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.
    Gu L; Waliany S; Kane SE
    PLoS One; 2009 Jul; 4(7):e6220. PubMed ID: 19593441
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
    Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
    Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
    Hynes NE; Dey JH
    Cancer Cell; 2009 May; 15(5):353-5. PubMed ID: 19411062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 51. GPR48, a poor prognostic factor, promotes tumor metastasis and activates β-catenin/TCF signaling in colorectal cancer.
    Wu J; Xie N; Xie K; Zeng J; Cheng L; Lei Y; Liu Y; Song L; Dong D; Chen Y; Zeng R; Nice EC; Huang C; Wei Y
    Carcinogenesis; 2013 Dec; 34(12):2861-9. PubMed ID: 23803691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
    De Lorenzo C; Troise F; Cafaro V; D'Alessio G
    Br J Cancer; 2007 Nov; 97(10):1354-60. PubMed ID: 17923870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.
    Shin HW; Choi H; So D; Kim YI; Cho K; Chung HJ; Lee KH; Chun YS; Cho CH; Kang GH; Kim WH; Park JW
    Gastroenterology; 2014 Aug; 147(2):430-442.e8. PubMed ID: 24846398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
    Ozbay T; Durden DL; Liu T; O'Regan RM; Nahta R
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):697-706. PubMed ID: 19636556
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.
    Anastasi S; Sala G; Huiping C; Caprini E; Russo G; Iacovelli S; Lucini F; Ingvarsson S; Segatto O
    Oncogene; 2005 Jun; 24(28):4540-8. PubMed ID: 15856022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription.
    Navarro D; Agra N; Pestaña A; Alonso J; González-Sancho JM
    Carcinogenesis; 2010 Mar; 31(3):394-401. PubMed ID: 20019092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.
    Arteaga CL
    Breast Cancer Res; 2003; 5(2):96-100. PubMed ID: 12631388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
    Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
    Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
    Lu Y; Zi X; Zhao Y; Pollak M
    Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.